Pegylated recombinant human hyaluronidase - Halozyme

Drug Profile

Pegylated recombinant human hyaluronidase - Halozyme

Alternative Names: PEG PH20; PEG rHuPH-20; pegvorhyaluronidase alpha; PEGylated reombinant human hyaluronidase - Halozyme; Pegylated rHuPH20

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Halozyme Therapeutics
  • Developer Eisai Co Ltd; Genentech; Halozyme Therapeutics; Scripps Health; University of California at San Francisco
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase I Cholangiocarcinoma; Gallbladder cancer; Solid tumours

Most Recent Events

  • 24 Oct 2017 Phase-I/II clinical trials in Gastric cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV)
  • 24 Oct 2017 Phase-I/II clinical trials in Oesophageal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 16 Oct 2017 Phase-I clinical trials in Cholangiocarcinoma (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, First-line therapy) in USA (IV) (NCT03267940)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top